CliffBio
small molecule

POSACONAZOLE

POSACONAZOLE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand namePOSACONAZOLE
Active ingredientPOSACONAZOLE
Strength300MG/16.7ML (18MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2023
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.